Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control
作者:Alex M. Aronov、Qing Tang、Gabriel Martinez-Botella、Guy W. Bemis、Jingrong Cao、Guanjing Chen、Nigel P. Ewing、Pamella J. Ford、Ursula A. Germann、Jeremy Green、Michael R. Hale、Marc Jacobs、James W. Janetka、Francois Maltais、William Markland、Mark N. Namchuk、Suganthini Nanthakumar、Srinivasu Poondru、Judy Straub、Ernst ter Haar、Xiaoling Xie
DOI:10.1021/jm900630q
日期:2009.10.22
anticancer drug design. A novel series of pyrimidylpyrrole ERK inhibitors has been identified. Discovery of a conformational change for lead compound 2, when bound to ERK2 relative to antitarget GSK3, enabled structure-guided selectivity optimization, which led to the discovery of 11e, a potent, selective, and orallybioavailableinhibitor of ERK.
N,N'-DISUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS
申请人:STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of
公开号:EP0516748A1
公开(公告)日:1992-12-09
SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS